Literature DB >> 33676119

A comprehensive assessment of environmental exposures and the medical history guides multidisciplinary discussion in interstitial lung disease.

Neal Dodia1, Diana Amariei1, Blaine Kenaa1, Doug Corwin1, Lydia Chelala2, E James Britt1, Ashutosh Sachdeva1, Irina G Luzina3, Jeffrey D Hasday3, Nirav G Shah1, Sergei P Atamas3, Teri J Franks4, Allen P Burke5, Stella E Hines1, Jeffrey R Galvin6, Nevins W Todd7.   

Abstract

BACKGROUND: Multidisciplinary discussion (MDD) is widely recommended for patients with interstitial lung disease (ILD), but published primary data from MDD has been scarce, and factors influencing MDD other than chest computed tomography (CT) and lung histopathology interpretations have not been well-described.
METHODS: Single institution MDD of 179 patients with ILD.
RESULTS: MDD consensus clinical diagnoses included autoimmune-related ILD, chronic hypersensitivity pneumonitis, smoking-related ILD, idiopathic pulmonary fibrosis, medication-induced ILD, occupation-related ILD, unclassifiable ILD, and a few less common pulmonary disorders. In 168 of 179 patients, one or more environmental exposures or pertinent features of the medical history were identified, including recreational/avocational, residential, and occupational exposures, systemic autoimmune disease, malignancy, medication use, and family history. The MDD process demonstrated the importance of comprehensively assessing these exposures and features, beyond merely noting their presence, for rendering consensus clinical diagnoses. Precise, well-defined chest CT and lung histopathology interpretations were rendered at MDD, including usual interstitial pneumonia, nonspecific interstitial pneumonia, and organizing pneumonia, but these interpretations were associated with a variety of MDD consensus clinical diagnoses, demonstrating their nonspecific nature in many instances. In 77 patients in which MDD consensus diagnosis differed from referring diagnosis, assessment of environmental exposures and medical history was found retrospectively to be the most impactful factor.
CONCLUSIONS: A comprehensive assessment of environmental exposures and pertinent features of the medical history guided MDD. In addition to rendering consensus clinical diagnoses, MDD presented clinicians with opportunities to initiate environmental remediation, behavior modification, or medication alteration likely to benefit individual patients with ILD. Published by Elsevier Ltd.

Entities:  

Keywords:  Autoimmune; Hypersensitivity; Idiopathic pulmonary fibrosis; Interstitial lung disease; Multidisciplinary discussion; Occupation; Smoking

Mesh:

Year:  2021        PMID: 33676119      PMCID: PMC7992253          DOI: 10.1016/j.rmed.2021.106333

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  40 in total

1.  Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?

Authors:  Kevin R Flaherty; Adin-Cristian Andrei; Talmadge E King; Ganesh Raghu; Thomas V Colby; Athol Wells; Nadir Bassily; Kevin Brown; Roland du Bois; Andrew Flint; Steven E Gay; Barry H Gross; Ella A Kazerooni; Robert Knapp; Edmund Louvar; David Lynch; Andrew G Nicholson; John Quick; Victor J Thannickal; William D Travis; James Vyskocil; Frazer A Wadenstorer; Jeffrey Wilt; Galen B Toews; Susan Murray; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

2.  Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors.

Authors:  Coralynn Sack; Ganesh Raghu
Journal:  Eur Respir J       Date:  2019-02-21       Impact factor: 16.671

Review 3.  Unclassifiable interstitial lung disease: a pathologist's perspective.

Authors:  Kirk D Jones
Journal:  Eur Respir Rev       Date:  2018-02-28

4.  Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study.

Authors:  Daniela J Lamas; Steven M Kawut; Emilia Bagiella; Nisha Philip; Selim M Arcasoy; David J Lederer
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

5.  Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease.

Authors:  Japnam S Grewal; Julie Morisset; Jolene H Fisher; Andrew M Churg; Ana-Maria Bilawich; Jennifer Ellis; John C English; Cameron J Hague; Nasreen Khalil; Jonathon Leipsic; John Mayo; Nestor L Muller; Darra Murphy; Joanne L Wright; Christopher J Ryerson
Journal:  Ann Am Thorac Soc       Date:  2019-04

6.  Enhancing Worker Health Through Clinical Decision Support (CDS): An Introduction to a Compilation.

Authors:  Margaret S Filios; Eileen Storey; Sherry Baron; Genevieve B Luensman; Richard N Shiffman
Journal:  J Occup Environ Med       Date:  2017-11       Impact factor: 2.162

Review 7.  Smoking-related lung disease.

Authors:  Jeffrey R Galvin; Teri J Franks
Journal:  J Thorac Imaging       Date:  2009-11       Impact factor: 3.000

8.  Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT.

Authors:  C Isabela S Silva; Nestor L Müller; David A Lynch; Douglas Curran-Everett; Kevin K Brown; Kyung Soo Lee; Man Pyo Chung; Andrew Churg
Journal:  Radiology       Date:  2008-01       Impact factor: 11.105

9.  A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre.

Authors:  Nazia Chaudhuri; Lisa Spencer; Melanie Greaves; Paul Bishop; Anshuman Chaturvedi; Colm Leonard
Journal:  J Clin Med       Date:  2016-07-27       Impact factor: 4.241

10.  My approach to interstitial lung disease using clinical, radiological and histopathological patterns.

Authors:  K O Leslie
Journal:  J Clin Pathol       Date:  2009-05       Impact factor: 3.411

View more
  1 in total

Review 1.  Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease.

Authors:  Nevins W Todd; Sergei P Atamas; Stella E Hines; Irina G Luzina; Nirav G Shah; Edward J Britt; Andrew J Ghio; Jeffrey R Galvin
Journal:  Expert Rev Respir Med       Date:  2022-01-31       Impact factor: 3.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.